Onconova Therapeutics to Participate in Three Investment Conferences During the Month of March

Rhea-AI Summary

Onconova Therapeutics, a biopharmaceutical firm focused on cancer treatments, announced participation in three virtual investment conferences in March 2021. Steven Fruchtman, M.D., will be attending:

• H.C. Wainwright Global Life Sciences Virtual Conference (March 9-10)
• Virtual 33rd Annual Roth Conference (March 15-17)
• Maxim Group Emerging Growth Virtual Conference (March 17-18)

The company also plans to start a Phase 1 trial for its multi-kinase inhibitor, ON 123300, in the U.S. this year, while ongoing studies for oral rigosertib target KRAS+ lung cancer patients.

NEWTOWN, PA., March 01, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, M.D., President and Chief Executive Officer, will participate in three virtual investment conferences during the month of March, as follows:

• The H.C. Wainwright Global Life Sciences Virtual Conference with one-on-one meetings being held March 9-10, 2021
• The Virtual 33rd Annual Roth Conference with one-on-one meetings being held March 15-17, 2021
• The Maxim Group Emerging Growth Virtual Conference being held March 17-18, 2021 with one-on-one meetings scheduled after the event
  

The Roth Capital Partners presentation will be prerecorded and available in the Investors & Media section of the Company’s website beginning today. Institutional and other investors interested in scheduling a one-on-one meeting with Onconova during any of these conferences should contact their sales representative at the sponsoring investment bank.

About Onconova Therapeutics, Inc.
Onconova Therapeutics is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.

Onconova’s novel, proprietary multi-kinase inhibitor ON 123300 is planned to begin a dose-escalation and expansion Phase 1 trial in the U.S. in the first half of 2021, and a dose-escalation and expansion Phase 1 trial is currently underway in China.

Onconova’s product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab. In addition, Onconova has commenced preclinical work investigating rigosertib in COVID-19.

For more information, please visit www.onconova.com.

Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. These statements relate to Onconova’s expectations regarding the registered direct offering, its patents and clinical development plans including [patient enrollment timelines and] indications for its product candidates. Onconova has attempted to identify forward-looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes. Although Onconova believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including the success and timing of Onconova's clinical trials and regulatory agency and institutional review board approvals of protocols, Onconova’s ability to continue as a going concern, the need for additional financing, Onconova’s collaborations, market conditions and those discussed under the heading "Risk Factors" in Onconova's most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q. Any forward-looking statements contained in this release speak only as of its date. Onconova undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Contact information

Company Contact:
Avi Oler
Onconova Therapeutics, Inc.
267-759-3680
ir@onconova.us
https://www.onconova.com/contact/ 

Investor Contact:
LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
kgolodetz@lhai.com

 

FAQ

What conferences will ONTX participate in March 2021?

Onconova Therapeutics (ONTX) will participate in the H.C. Wainwright Global Life Sciences Virtual Conference, the Virtual 33rd Annual Roth Conference, and the Maxim Group Emerging Growth Virtual Conference.

What is the timeline for ONTX's clinical trials in 2021?

Onconova plans to begin a Phase 1 trial for its multi-kinase inhibitor, ON 123300, in the U.S. in the first half of 2021.

What is the focus of Onconova Therapeutics?

Onconova Therapeutics focuses on developing novel products to treat cancer, including proprietary targeted anti-cancer agents.

What is the current status of ONTX's rigosertib study?

The oral rigosertib is in a Phase 1 investigator-initiated study targeting KRAS+ lung adenocarcinoma patients in combination with nivolumab.